PSMA/SSTR2/GRPR-targeted radioligand therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PSMA/SSTR2/GRPR-targeted radioligand therapy, covering 2026-03-11 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [Phase 1]